PROGRAM SYLLABUS Jointly provided by and This activity is supported by educational funding provided by Amgen.
CONTENTS Program Overview/Statement of Need... Page 3 Target Audience and Learning Objectives... Page 3 CME Statements... Page 4-5 Disclosures... Page 5-6 Steering Committee... Pages 7-8 Faculty... Page 9 ADDITIONAL PACKET CONTENTS Participant Survey and CME/MOC Evaluation... Front of packet After filling out the Activity Survey, Post-activity Survey, and CME/MOC Evaluation, please separate from packet and return to onsite staff Program Slides Copy of presentation slides with space for note-taking 2018 Rockpointe A CME-certified, MOC-eligible Grand Rounds Activity Page 2
PROGRAM OVERVIEW/STATEMENT OF NEED USF Health and Rockpointe welcome you to Improving Outcomes for Patients with Severe Hypercholesterolemia, a CME-certified, MOC-eligible Grand Rounds activity designed to give medical professionals the latest news and information on the management of patients with hypercholesterolemia. Hypercholesterolemia, particularly low-density lipoprotein cholesterol (LDL-C) elevation, is a major driver of atherosclerotic cardiovascular disease (ASCVD). Lipid-lowering therapies (mainly in combination with statins) are the primary treatment approach to lower LDL-C and reduce CVD risk. However, intensive statin therapy lowers CVD risk only by ~50%, leaving many patients at excessively high residual CVD risk. Ezetimibe, which reduces absorption of cholesterol from the intestine, reduces LDL-C levels by an additional 20%-25% and modestly improves clinical outcomes when added to statin therapy. Recently approved PCSK9 inhibitors also produce robust LDL-C reduction when coadministered with statins and have been shown to improve clinical outcomes in patients with ASCVD. Improving Outcomes for Patients with Severe Hypercholesterolemia will explore all of these treatment options and their safety/efficacy profiles, while also providing participants with insights on practical applications in clinical practice to improve the outcomes of their patients with severe or difficult-to-treat hypercholesterolemia. TARGET AUDIENCE This activity is intended for clinical cardiologists, internists, and other clinicians tasked with treating and establishing partnerships with ASCVD patients. EDUCATIONAL OBJECTIVES This program is designed to address the following IOM competencies: provide patientcentered care and employ evidence-based practice. At the conclusion of this activity, participants should be able to demonstrate the ability to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements as appropriate Conduct appropriate diagnosis of familial hypercholesterolemia and implement appropriate treatment and rationale for cascade screening of the families Differentiate the clinical properties of new and emerging pharmacologic approaches to reduce LDL-C and lower CVD risk Analyze the potential utility of new LDL-C lowering agents used in combination with statins to reduce CVD risk in patients who have ASCVD EOE/ADA USF is an Equal Opportunity / Affirmative Action / Equal Access Institution. 2018 Rockpointe A CME-certified, MOC-eligible Grand Rounds Activity Page 3
ACCREDITATION This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians. For information about accreditation of this activity, please email: cpdsupport@health.usf.edu. CREDIT DESIGNATION USF Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. MOC Points available for Internal Medicine General, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology Board Certified Physicians. FEE AND RECEIVING CME/MOC CREDIT There is no fee for this educational activity. To receive CME credit the participant must: Participate in this one-hour-long program; Sign in on the sheet provided by the host coordinator; Complete the appropriate survey/evaluation forms; Return the evaluation forms to the host coordinator. To receive ABIM MOC Points for Internal Medicine, General; Cardiovascular Disease; Clinical Cardiac Electrophysiology; Interventional Cardiology Board Certified Physicians: During registration, physicians seeking ABIM MOC Points will be required to provide: - ABIM six-digit ID number - First and last name - Date of birth (mm/dd) - ABIM specialty board - Permission for USF Health to share completion data with ACCME, who will transmit same on their behalf to ABIM 2018 Rockpointe A CME-certified, MOC-eligible Grand Rounds Activity Page 4
After the course, physicians seeking ABIM Points will be required to take an evaluation/post-test and pass with a score of 60% Within 60 days of the end of the activity, USF Health will upload to ACCME the participant data of physicians who have met the ABIM MOC Points requirements; ACCME will transmit the same to ABIM SPECIAL SERVICES Event staff will be glad to assist you with any special needs. DISCLAIMER The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient s medical condition. NON-ENDORSEMENT USF Health does not endorse any product, material, or service mentioned in association with this activity. POTENTIAL CONFLICTS OF INTEREST USF Health endorses the standards of the ACCME that require everyone in a position to control the content of an accredited educational activity to disclose all financial relationships with commercial interests that are related to the content of the educational activity. All accredited activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when individuals in a position to control the content of an accredited educational activity have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. USF Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services. DISCLOSURES Steering Committee The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests: Alan Brown, MD, FACC, FAHA, FNLA, FASPC: Advisory Board: Akcea Therapeutics, Amgen, Kowa, Regeneron, Sanofi; Speaker s Bureau: Akcea Therapeutics, Amgen, Kowa, Regeneron, Sanofi 2018 Rockpointe A CME-certified, MOC-eligible Grand Rounds Activity Page 5
James A. Underberg, MD, MS, FNLA: Advisory Board: Akcea Therapeutics, Alexion, Ambry, Amgen, Regeneron, Sanofi; Consultant: Amgen; Research: Aegerion, Pfizer; Speaker s Bureau: Akcea Therapeutics, Aegerion, Alexion, Amarin, Amgen, Kowa, Regeneron, Sanofi Non-faculty Content Contributors Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests: Allan Chen, MD; Joseph J. Namey Jr., DO, MACOI, FACP; Jaclyn Capazola; Barry Watkins, PhD; Blair St. Amand: Nothing to disclose 2018 Rockpointe A CME-certified, MOC-eligible Grand Rounds Activity Page 6
STEERING COMMITTEE Improving Outcomes for Patients with Severe Hypercholesterolemia ALAN BROWN, MD, FACC, FAHA, FNLA, FASPC President, National Lipid Association Director, Division of Cardiology Advocate Heart Institute at Advocate Lutheran General Hospital Co-director, Cardiology Service Line, Advocate Medical Group Naperville, IL Alan Brown, MD, FACC, FAHA, FNLA, FASPC has been the Director of the Prevention Center/Lipid Clinic for Midwest Heart Specialists since its inception in 1985. He is a practicing interventional and preventive cardiologist and was appointed Clinical Associate Professor of Medicine and Cardiology at Loyola from 1993 until the present. Dr. Brown is board-certified in internal medicine, cardiology, echocardiography, and clinical lipidology. He is currently the Director of the Division of Cardiology at the Advocate Heart Institute at Advocate Lutheran General Hospital in Park Ridge, IL, as well as the Co-director of the Cardiology Service Line for Advocate Medical Group/Advocate Health Care. Dr. Brown has served as Governor/President of the Illinois Chapter of the American College of Cardiology (ACC) and subsequently was elected Chairman of the Board of Governors for the ACC in 2004. He is a Fellow of the American Heart Association, the National Lipid Association and the ACC and has been a member of the ACC's Prevention of Cardiovascular Disease Committee and Annual Scientific Program Committee. He is currently on the ACC Task Force for Appropriate Use Criteria. Dr. Brown served as a member of the ACC Board of Trustees from 2003 through 2006. He is currently President of the National Lipid Association and a member of the Board of Directors for the American Society for Preventative Cardiology. Dr. Brown has authored numerous articles in the field of lipid management and prevention, as well as two book chapters. He is the host of Lipid Luminations, an internet radio show on Reach MD that focuses on lipid topics through interviews with national thought-leaders. 2018 Rockpointe A CME-certified, MOC-eligible Grand Rounds Activity Page 7
STEERING COMMITTEE JAMES A. UNDERBERG, MD, MS, FNLA Immediate Past-President, National Lipid Association Clinical Assistant Professor of Medicine NYU School of Medicine and NYU Center for Prevention of Cardiovascular Disease Director, Bellevue Hospital Lipid Clinic New York, NY James A. Underberg, MD, MS, FNLA is a clinical lipidologist and a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology, a Fellow of the National Lipid Association, and the Immediate Past-President of the National Lipid Association. He is a board member of the National Lipid Association and the Foundation of the National Lipid Association and is President-Elect of the American Board of Clinical Lipidology. Dr. Underberg s clinical interests focus on the clinical management of patients with lipids and lipoprotein disorders, hypertension management, and cardiovascular disease prevention. He maintains an active clinical-research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology. He sees patients both at Bellevue Hospital and in a university-based private-practice setting. 2018 Rockpointe A CME-certified, MOC-eligible Grand Rounds Activity Page 8